Bayforest Capital Ltd grew its holdings in Axcelis Technologies, Inc. (NASDAQ:ACLS – Free Report) by 452.0% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,217 shares of the semiconductor company’s stock after purchasing an additional 3,453 shares during the period. Bayforest Capital Ltd’s holdings in Axcelis Technologies were worth $294,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Axcelis Technologies by 1.0% in the first quarter. Vanguard Group Inc. now owns 4,439,902 shares of the semiconductor company’s stock valued at $220,530,000 after purchasing an additional 43,768 shares during the last quarter. Reinhart Partners LLC. raised its holdings in shares of Axcelis Technologies by 5.4% in the second quarter. Reinhart Partners LLC. now owns 1,518,544 shares of the semiconductor company’s stock valued at $105,828,000 after purchasing an additional 77,522 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of Axcelis Technologies by 7.6% in the first quarter. American Century Companies Inc. now owns 1,140,495 shares of the semiconductor company’s stock valued at $56,648,000 after purchasing an additional 80,399 shares during the last quarter. Boston Trust Walden Corp raised its holdings in shares of Axcelis Technologies by 2.4% in the second quarter. Boston Trust Walden Corp now owns 845,911 shares of the semiconductor company’s stock valued at $58,952,000 after purchasing an additional 19,579 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Axcelis Technologies by 7.5% in the first quarter. Goldman Sachs Group Inc. now owns 635,393 shares of the semiconductor company’s stock valued at $31,560,000 after purchasing an additional 44,275 shares during the last quarter. 89.98% of the stock is currently owned by institutional investors and hedge funds.
Axcelis Technologies Trading Up 4.2%
ACLS stock opened at $83.77 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.01 and a quick ratio of 4.26. The company has a fifty day moving average price of $85.56 and a two-hundred day moving average price of $69.63. Axcelis Technologies, Inc. has a one year low of $40.40 and a one year high of $102.93. The stock has a market cap of $2.63 billion, a price-to-earnings ratio of 17.13 and a beta of 1.75.
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on ACLS. Wall Street Zen upgraded shares of Axcelis Technologies from a “hold” rating to a “buy” rating in a report on Saturday, October 11th. B. Riley lifted their price objective on shares of Axcelis Technologies from $58.00 to $75.00 and gave the company a “neutral” rating in a report on Wednesday, June 18th. Bank of America cut shares of Axcelis Technologies from a “neutral” rating to an “underperform” rating and raised their target price for the company from $81.00 to $90.00 in a research note on Monday. Benchmark raised shares of Axcelis Technologies from a “hold” rating to a “buy” rating and set a $105.00 target price for the company in a research note on Thursday, October 2nd. Finally, DA Davidson raised their target price on shares of Axcelis Technologies from $90.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, October 2nd. Three research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $97.00.
Check Out Our Latest Research Report on Axcelis Technologies
About Axcelis Technologies
Axcelis Technologies, Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips in the United States, Europe, and Asia Pacific. The company offers high energy, high current, and medium current implanters for various application requirements.
See Also
- Five stocks we like better than Axcelis Technologies
- 3 Small Caps With Big Return Potential
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- How to Invest in Biotech Stocks
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- What is a Secondary Public Offering? What Investors Need to Know
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Axcelis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcelis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
